Last reviewed · How we verify
Interferon beta-1b, FRP within 15 days after randomization
Interferon beta-1b, marketed by Bayer, is an established treatment in the pharmaceutical market with a key composition patent expiring in 2028. The drug's primary strength lies in its well-documented mechanism and clinical efficacy, supported by robust trial results. The primary risk to consider is the potential increase in competition as the key patent approaches expiration.
At a glance
| Generic name | Interferon beta-1b, FRP within 15 days after randomization |
|---|---|
| Sponsor | Bayer |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Rehabilitation Study in MS Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: